Latest News
News from the FDA/CDC
FDA approves new formulation of Hyrimoz adalimumab biosimilar
The agency approved a higher-concentration formulation of Hyrimoz for its previous indications, including rheumatoid arthritis and psoriasis.
Latest News
Anifrolumab shows promise in refractory discoid lupus erythematosus
Anifrolumab improved symptoms and activity of DLE within 2 months in a study of eight women.
Latest News
New data forecast more oral PDE4 inhibitors for psoriasis
The phase 2b data suggest that the drug, called orismilast, “is a potential new addition to the psoriasis armamentarium,” said Lars E. French, MD...
From the Journals
Poor bone health is a ‘robust’ dementia risk factor
“Persons with subclinical, incipient dementia may have poor bone health due to the dementia process instead of vice versa.”
From the Journals
CT results in myositis inform cancer screening strategies
Patients with the autoantibody anti–TIF1-gamma had the highest diagnostic yield, while patients under 40 years old had a high frequency of false...
From the Journals
Tofacitinib may have possible protective effect against ILD in RA
“Most of the biologic therapies had similar rates of developing ILD, but the JAK inhibitor tofacitinib had a reduced risk,” said study first...
Conference Coverage
New JAK inhibitor study data confirm benefit in alopecia areata
Deuruxolitinib (CTP-543), an inhibitor of the JAK1 and JAK2 enzymes, has the potential to become the second JAK inhibitor available for the...
Conference Coverage
Link between knee pain, sleep disturbance related to daily activities
Findings suggested that it’s only knee pain, not the severity of knee osteoarthritis, that’s significantly associated with sleep disturbances, and...
Feature
Nurse makes millions selling her licensing exam study sheets
Stephanee Beggs’ business developed in a “very unintentional” way.
From the Journals
Psoriatic arthritis treatment for women falls short, study suggests
Women with psoriatic arthritis who were treated with ustekinumab or a tumor necrosis factor inhibitor had lower response rates and persistence at...
Feature
After the Match: Next steps for new residents, unmatched
International medical graduates applied in record numbers to Match2023, according to the National Resident Matching Program.